Published in Nature on February 05, 2014
A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. Cell (2014) 1.62
Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Exp Med (2014) 1.59
De novo design of a four-fold symmetric TIM-barrel protein with atomic-level accuracy. Nat Chem Biol (2015) 1.45
Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog (2016) 1.42
A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice. PLoS One (2016) 1.40
Structural Basis of Zika Virus-Specific Antibody Protection. Cell (2016) 1.27
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer. Nature (2016) 1.12
Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A (2014) 1.06
A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology (2014) 1.03
Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. J Virol (2014) 1.00
Novel antigens for RSV vaccines. Curr Opin Immunol (2015) 0.99
Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. PLoS Pathog (2015) 0.96
Transplanting supersites of HIV-1 vulnerability. PLoS One (2014) 0.96
Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High-Resolution Cryoelectron Microscopy. Structure (2015) 0.94
Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc Natl Acad Sci U S A (2014) 0.92
A critical question for HIV vaccine development: which antibodies to induce? Science (2014) 0.91
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol (2015) 0.90
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat Commun (2016) 0.90
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med (2016) 0.87
Self-assembling protein nanoparticles in the design of vaccines. Comput Struct Biotechnol J (2015) 0.87
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. J Immunol Res (2015) 0.85
Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest (2015) 0.85
The coming of age of de novo protein design. Nature (2016) 0.84
Rapid search for tertiary fragments reveals protein sequence-structure relationships. Protein Sci (2014) 0.84
Rapid Fine Conformational Epitope Mapping Using Comprehensive Mutagenesis and Deep Sequencing. J Biol Chem (2015) 0.84
Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet (2015) 0.84
Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses. Hum Vaccin Immunother (2015) 0.83
Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses. J Virol (2014) 0.83
A site of varicella-zoster virus vulnerability identified by structural studies of neutralizing antibodies bound to the glycoprotein complex gHgL. Proc Natl Acad Sci U S A (2015) 0.83
A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci (2014) 0.83
RNA virus reverse genetics and vaccine design. Viruses (2014) 0.82
Options and obstacles for designing a universal influenza vaccine. Viruses (2014) 0.82
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. Proc Natl Acad Sci U S A (2016) 0.81
Variability in Humoral Immunity to Measles Vaccine: New Developments. Trends Mol Med (2015) 0.81
Applying contemporary immunology to elucidate heterologous effects of infant vaccines and to better inform maternal-infant immunization practices. Front Immunol (2015) 0.81
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus. PLoS One (2016) 0.81
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
Design of self-assembling transmembrane helical bundles to elucidate principles required for membrane protein folding and ion transport. Philos Trans R Soc Lond B Biol Sci (2017) 0.80
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Proc Natl Acad Sci U S A (2016) 0.79
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform. Curr Opin Virol (2015) 0.79
A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. PLoS One (2016) 0.79
Computational tools for epitope vaccine design and evaluation. Curr Opin Virol (2015) 0.79
Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest (2015) 0.79
An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold. Angew Chem Int Ed Engl (2015) 0.79
Multiple B-cell epitope vaccine induces a Staphylococcus enterotoxin B-specific IgG1 protective response against MRSA infection. Sci Rep (2015) 0.78
A Framework to Simplify Combined Sampling Strategies in Rosetta. PLoS One (2015) 0.78
Epitope specific T-cell responses against influenza A in a healthy population. Immunology (2015) 0.78
Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol (2016) 0.77
Integrating gene synthesis and microfluidic protein analysis for rapid protein engineering. Nucleic Acids Res (2015) 0.77
Identification and validation of a linear protective neutralizing epitope in the β-pore domain of alpha toxin. PLoS One (2015) 0.77
Emerging Vaccine Technologies. Vaccines (Basel) (2015) 0.77
Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5. Proteins (2014) 0.77
Protein Crystallography in Vaccine Research and Development. Int J Mol Sci (2015) 0.77
Soluble cysteine-rich tick saliva proteins Salp15 and Iric-1 from E. coli. FEBS Open Bio (2014) 0.76
Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines (2015) 0.76
Protection conferred by virus-like particle vaccines against respiratory syncytial virus infection in mice by intranasal vaccination. Hum Vaccin Immunother (2015) 0.76
Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Vaccine (2016) 0.76
Algorithms for protein design. Curr Opin Struct Biol (2016) 0.76
Vaccine Design for H5N1 Based on B- and T-cell Epitope Predictions. Bioinform Biol Insights (2016) 0.76
Addressing viral resistance through vaccines. Future Virol (2015) 0.75
Residue-centric modeling and design of saccharide and glycoconjugate structures. J Comput Chem (2016) 0.75
Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice. Mol Ther (2015) 0.75
Type VI secretion system sheaths as nanoparticles for antigen display. Proc Natl Acad Sci U S A (2016) 0.75
Synthesis of multivalent glycopeptide conjugates that mimic an HIV epitope. Tetrahedron (2016) 0.75
Reverse Engineering of Vaccine Antigens Using High Throughput Sequencing-enhanced mRNA Display. EBioMedicine (2015) 0.75
Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine (2016) 0.75
Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Glycobiology (2014) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Modeling and docking of antibody structures with Rosetta. Nat Protoc (2017) 0.75
Probing the Impact of Local Structural Dynamics of Conformational Epitopes on Antibody Recognition. Biochemistry (2016) 0.75
Exploring human antimicrobial antibody responses on a single B cell level. Clin Vaccine Immunol (2017) 0.75
In silico CD4+, CD8+ T-cell and B-cell immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus. EXCLI J (2017) 0.75
The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens. Expert Rev Vaccines (2014) 0.75
Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan. J Virol (2016) 0.75
Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. MAbs (2014) 0.75
The promise and challenge of epitope-focused vaccines. Hum Vaccin Immunother (2016) 0.75
Rational design of TNFα binding proteins based on the de novo designed protein DS119. Protein Sci (2016) 0.75
Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present. PLoS One (2015) 0.75
Staged heterogeneity learning to identify conformational B-cell epitopes from antigen sequences. BMC Genomics (2017) 0.75
The germinal center antibody response in health and disease. F1000Res (2016) 0.75
A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. AIDS Res Hum Retroviruses (2015) 0.75
Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother (2016) 0.75
Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. MBio (2017) 0.75
Classification of self-assembling protein nanoparticle architectures for applications in vaccine design. R Soc Open Sci (2017) 0.75
In silico analysis of Shiga toxins (Stxs) to identify new potential vaccine targets for Shiga toxin-producing Escherichia coli. In Silico Pharmacol (2017) 0.75
Reprogramming cellular functions with engineered membrane proteins. Curr Opin Biotechnol (2017) 0.75
What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise. Cold Spring Harb Perspect Biol (2017) 0.75
Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope. J Virol (2017) 0.75
Molecular Evolutionary Constraints that Determine the Avirulence State of Clostridium botulinum C2 Toxin. J Mol Evol (2017) 0.75
Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a model of porcine circovirus type 2. Int J Nanomedicine (2017) 0.75
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
The global distribution and burden of dengue. Nature (2013) 27.92
NMR View: A computer program for the visualization and analysis of NMR data. J Biomol NMR (1994) 22.42
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis (2011) 14.93
Design of a novel globular protein fold with atomic-level accuracy. Science (2003) 13.06
Protein structure prediction using Rosetta. Methods Enzymol (2004) 12.05
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet (2013) 8.18
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol (2011) 7.33
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 4.92
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Using circular dichroism collected as a function of temperature to determine the thermodynamics of protein unfolding and binding interactions. Nat Protoc (2006) 3.48
Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci U S A (2010) 2.68
Principles for designing ideal protein structures. Nature (2012) 2.50
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Vaccines for the twenty-first century society. Nat Rev Immunol (2011) 2.34
Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science (2011) 2.17
Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature (1987) 2.00
Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure (2010) 1.91
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
HELANAL: a program to characterize helix geometry in proteins. J Biomol Struct Dyn (2000) 1.82
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci Transl Med (2012) 1.45
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 1.39
Determination of the folding of proteins as a function of denaturants, osmolytes or ligands using circular dichroism. Nat Protoc (2006) 1.32
Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. J Mol Biol (2010) 1.14
Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope. J Mol Biol (2011) 1.12
Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat Struct Mol Biol (2012) 1.11
A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate. J Immunol Methods (2010) 1.10
RosettaHoles2: a volumetric packing measure for protein structure refinement and validation. Protein Sci (2010) 1.10
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis (2011) 1.03
Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J (2013) 0.98
Allosteric activation of the RNF146 ubiquitin ligase by a poly(ADP-ribosyl)ation signal. Nature (2014) 1.12
Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun (2015) 1.02
High-resolution structure of the Shigella type-III secretion needle by solid-state NMR and cryo-electron microscopy. Nat Commun (2014) 1.00
Emergence of a catalytic tetrad during evolution of a highly active artificial aldolase. Nat Chem (2016) 0.77
Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun (2017) 0.75